Skip to content

Clinical trials

Phase 1/2 Lung Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Phase 1/2 Country / region: China Clear all

52 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20142
20153
20165
20178
20184
20193
20201
20214
20222
20237
20246
20251
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Recruiting14
Unknown status14
Active, not recruiting3
Withdrawn3
Not yet recruiting2
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fuda Cancer Hospital, Guangzhou9
Chongqing Precision Biotech Co., Ltd2
Essen Biotech2
Shenzhen Geno-Immune Medical Institute2
3H Pharmaceuticals Co., Ltd.1
Ahon Pharmaceutical Co., Ltd.1
Akeso1
Astellas Pharma Global Development, Inc.1
Avenzo Therapeutics, Inc.1
Avistone Biotechnology Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms52
Carcinoma, Non-Small-Cell Lung17
Colorectal Neoplasms11
Pancreatic Neoplasms9
Stomach Neoplasms9
Breast Neoplasms8
Ovarian Neoplasms7
Neoplasms6
Colonic Neoplasms5
Esophageal Neoplasms5

Trials

Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.